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Abstract
Kallikreins-related peptidases (KLKs) are serine proteases and have been implicated in the desquamation process of the skin.
Their activity is tightly controlled by epidermal protease inhibitors like the lympho-epithelial Kazal-type inhibitor (LEKTI).
Defects of the LEKTI-encoding gene serine protease inhibitor Kazal type (Spink)5 lead to the absence of LEKTI and result in
the genodermatose Netherton syndrome, which mimics the common skin disease atopic dermatitis. Since many KLKs are
expressed in human skin with KLK5 being considered as one of the most important KLKs in skin desquamation, we
proposed that more inhibitors are present in human skin. Herein, we purified from human stratum corneum by HPLC
techniques a new KLK5-inhibiting peptide encoded by a member of the Spink family, designated as Spink9 located on
chromosome 5p33.1. This peptide is highly homologous to LEKTI and was termed LEKTI-2. Recombinant LEKTI-2 inhibited
KLK5 but not KLK7, 14 or other serine proteases tested including trypsin, plasmin and thrombin. Spink9 mRNA expression
was detected in human skin samples and in cultured keratinocytes. LEKTI-2 immune-expression was focally localized at the
stratum granulosum and stratum corneum at palmar and plantar sites in close localization to KLK5. At sites of plantar
hyperkeratosis, LEKTI-2 expression was increased. We suggest that LEKTI-2 contributes to the regulation of the
desquamation process in human skin by specifically inhibiting KLK5.
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Introduction
The skin protects us from water loss and mechanical damage.
The surface-exposed epidermis, a self-renewing stratified squa-
mous epithelium composed of several layers of keratinocytes, is
most important for the barrier defense against these challenges.
Keratinocytes in the outmost stratum corneum (SC) of the
epidermis are shed off and replaced by newly differentiated cells
originating from epidermal stem cells located in the basal layer.
They undergo a specific differentiation process and form the
cornified envelope, which is a rigid and insoluble protein and lipid
structure with essential properties of the barrier function [1,2].
Recent discoveries have highlighted the importance of protease-
inhibitors and proteases as key players in the desquamation
process and in epidermal barrier function.
Human tissue kallikreins, or kallikrein-related peptidases (KLK),
are the largest family of trypsin or chymotrypsin-like secreted serine
proteases encoded by 15 genes on chromosome region 19q13.4 [3].
At least eight KLKs are expressed in normal skin, among which
KLK5, KLK7, KLK8 and KLK14 have been reported to be most
important [4–6]. KLKs are capable of cleaving corneodesmosomes
[7–10] and are thought to be key regulators of the desquamation
process. Epidermal overexpression of KLK7 resulted in pathologic
skin changes with increased epidermal thickness, hyperkeratosis,
dermal inflammation, and severe pruritus [11]. The activity of the
KLKs is regulated by the pH and specific protease inhibitors in
human skin. The importance of epithelial protease inhibitors has
been revealed impressively in Netherton Syndrome (NS; OMIM
256500),anautosomalrecessivedisordercausedbymutationsinthe
serine protease inhibitor Kazal-type 5 (Spink5) gene [12]. NS
presents as an ichthyosiform dermatosis with variable erythroder-
ma, hair-shaft defects (bamboo hair), atopic features, and growth
retardation [13]. Lymphoepithelial Kazal-type-related inhibitor
(LEKTI) [14], the product of Spink5, includes in its primary
structure 15 different serine protease inhibitory domains [14]. The
inhibitory functions of LEKTI are highly diverse. Inhibitory
activities are directed toward trypsin, plasmin, subtilisin A,
cathepsin G, and human neutrophil elastase [15]. Though LEKTI
is absent, NS patients can still develop hyperkeratosis – a clinical
sign of inhibited desquamation.
Therefore, we speculated that more KLK inhibitors are present
in human skin generating a complex network of KLKs and their
inhibitors to control the desquamation process. Since KLK5 is
thought to be one of the most important enzymes involved in this
process, we started a preparative attempt to identify KLK5
inhibitors in human stratum corneum. Herein we report the
identification of a new protease inhibitor LEKTI-2 and its gene
Spink9, which specifically inhibits KLK5.
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Identification of a new KLK5-inhibiting peptide in human
Stratum corneum
To follow the hypothesis that specific inhibitors for KLK5 exist in
human skin, extracts from healthy persons’ SC were analyzed for
KLK5-inhibiting activity. Preparative reverse-phase HPLC (RP-
HPLC)wasusedtoseparateheparin-bound cationic peptides. Results
from KLK5-inhibiting activity revealed a fraction (Fig. 1A), which
was further purified by analytical RP-HPLC using a C2C18-column
(data not shown). SDS-PAGE analysis (Fig. 1B) of these HPLC
fractions, eluting at low acetonitrile concentration and containing
KLK5-inhibitory activity showed the presence of a 7-kDa peptide.
Electrospray-ionisationmassspectrometry(ESI-MS)analysis(Fig.1C)
resulted in a principal ion corresponding to a mass of 7058.19 Da.
Da. N-terminal sequencing of the dominant fraction yielded a
sequence of 25 residues (TKQMVDXSHYKKLPPGQQRFX-
HHMY; Fig. 1D). A blast search using the 25-residue sequence
retrieved no matches in any protein/gene/EST databases, suggesting
a novel human gene may encode this sequence.
The KLK5-inhibiting peptide is encoded by Spink9
To identify the gene corresponding to the amino acid sequence, a
BLAT search with the N-terminal 25-residue sequence of the novel
peptide (where6was replaced by the cysteine residue) against the
April 2003 human genome assembly localized this sequence to a
chromosome 5 clone RP11-373N22 on 5p33.1 (Fig. 2A). Subsequent
analysis of the retrieved RP11-373N22 DNA sequence identified two
putative exons exactly encoding the isolated peptide (Fig. 1). Based on
the generated theoretical partial DNA sequence, gene-specific
primers were designed to perform 39-a n d5 9-RACE. The full-length
cDNA sequence (453 bp) was completed by combining the
overlapping sequences from each PCR product and then confirmed
by a long distance PCR (Fig. 2C; GenBank accession
No. AY396740). Alignment of the mRNA sequence against human
genome sequences clearly indicated that each unique mRNA
segment represents an individual exon and that all introns are
flanked by the consensus donor and acceptor splice sites conforming
to the GT/AG rule (Fig. 2B; data not shown). This gene contains an
open reading frame of 261 nucleotides encoding a protein of 86
amino acids; a polyadenylation signal (AAUAAA) is situated 13
nucleotides 59 of the polyadenine tail (Fig. 2C). By SMART analysis,
the 16 residues from the first Met are a leader sequence containing a
signal peptide while the last 55 residues correspond to a typical Kazal
domain. A BLAST search revealed that this Kazal domain is about
33% identical (50% similar) and 32% identical (40% similar) to
domains 2 and 15 of human Lekti, respectively, (Fig. 2D) that is
encoded by Spink5, the defective gene in Netherton syndrome [12].
These three Kazal domains possess similar domain patterns,
including a conserved tyrosine residue, disulfide bonds and the
residue numbers spacing the cysteine residues. Only the P1 residue of
the putative active site is different, suggesting they might have
different substrate binding modes. Therefore, we designated this
novel gene as serine protease inhibitor Kazal-type 9 with the gene
symbol Spink9, which was approved later by the HUGO gene
nomenclature committee, while its protein product was named
lympho-epithelial Kazal-type inhibitor 2 (LEKTI-2).
Spink9 is expressed in human skin and in cultured
keratinocytes
To investigate the cellular source of LEKTI-2, both RT-PCR
and real-time RT-PCR were used to determine its mRNA
expression. Expression of Spink9 mRNA was detected in skin
samples from foreskin and cultured primary keratinocytes (Fig. 3A).
In addition, its expression was also detected in thymus, tonsils,
testis, placenta and brain but not in other tissue samples tested
(Fig. 3A). In cultured primary keratinocytes, the expression level of
Spink9 mRNA was increased up to 10-fold over the time course
during calcium-induced differentiation, suggesting that Spink9 is
produced by epithelial terminally differentiating keratinocytes.
LEKTI-2 is expressed at palmar and plantar sites
To analyze LEKTI-2 protein expression, we generated affinity-
purified polyclonal LEKTI-2 antibodies. Westernblot analyses
performed with rLEKTI-2, purified natural LEKTI-2 and stratum
corneum extracts revealed antigen specificity of the antibodies
(Fig. 4), which was further confirmed by blocking experiments
using recombinant LEKTI-2. Subsequently, LEKTI-2 immuno-
histochemistry was performed to localize LEKTI-2 expression in
human skin samples. LEKTI-2 immunoreactivity was detected in
the stratum granulosum and SC of human skin at the palms (inner
sides) of hands and feet (n=8) but no visible immunoreactivity was
detected at other sites of healthy human skin (n=16) (Fig. 5).
Recombinant LEKTI-2 is a specific KLK5-inhibitor
To verify the protease inhibition of the purified LEKTI-2,
recombinant LEKTI-2 was tested for its protease inhibitory
activity. KLK5 was inhibited in a dose dependent manner.
Assuming full competitivity of binding (alpha=infinitive) Baici
Model was used to calculate Ki (approximately 250 nM, Fig. 6).
Interestingly, no other tested serine proteases, which include
KLK7, KLK14, trypsin and chymotrypsin were inhibited by
LEKTI-2 (Table 1, Fig. 6).
LEKTI-2 and KLK5 are in close localization in vivo
To visualize whether LEKTI-2 and KLK5 localize to the same
site in human skin, fluorescent microscopic analyses were
performed. LEKTI-2 fluorescent staining revealed granular-like
structures inside the keratinocytes at the stratum granulosum and
an intercellular staining in this area and in the SC (Fig. 7). KLK5-
staining revealed intercellular expression pattern at the same area.
However, a clear co-localization was not observed.
LEKTI-2 is highly expressed at sites of hyperkeratosis
Hyperkeratosis at the palmar sites can occur due to increased
local mechanical pressure and lead to hyperkeratosis in the form of
clavus. Interestingly, LEKTI-2 immunoreactivity was shown to be
markedly induced at lesions of clavi (Fig. 8). Since KLK5 is one of
the major proteases for desquamation, increased LEKTI-2
expression at the sites of clavi might contribute to the
hyperkeratosis of these lesions.
Discussion
In this study we aimed to identify major substances that might
contribute to the epithelial barrier shield by inhibiting the
epidermal serine protease KLK5. We identified a new peptide
termed LEKTI-2 as a specific inhibitor for KLK5, which is
encoded by Spink9, a novel member of the Spink gene family. Our
findings give evidence for the importance of LEKTI-2 in
epidermal desquamation and provide new insight to the complex
protease-protease inhibitor interaction in human skin.
LEKTI-2 expression shows some similarities to the expression of
LEKTI, which was demonstrated to be expressed in lamellar
bodies, likely the granular-like structures in our fluorescent staining,
and secreted into the intercellular space, in the uppermost stratum
granulosum [16–18]. Electron microscopy studies revealed that
LEKTI and KLK7 are transported separately in the lamellar
LEKTI-2 in Human Skin
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PLoS ONE | www.plosone.org 3 February 2009 | Volume 4 | Issue 2 | e4372Figure 2. Molecular identification of the Spink9 gene. (A) Schematic physical map of human SPINK genes locus (5q33.1). Genes are ordered
from centromere (left hand side) to telomere (right hand side). (B) Schematic diagram of the Spink9 gene, based on its cDNA isolated from foreskin-
derived keratinocyte identified by RT-PCR. It consists of four exons and three introns. The positions of the exons (boxes) and introns (curve lines) of
Spink9 are deduced by comparing its full-length cDNA sequence with the corresponding genomic DNA. 59/39-UTRs and coding sequences are
indicated by gray- and green-filled boxes, respectively. (C) The full-length cDNA sequence of Spink9 and its predicted protein sequence. The N-
terminal signal peptide (residues 1–16; underlined) and the Kazal domain (residues 32–86; double-underlined) were detected with the SMART
algorithm. The poly(A) signal site was coloured green. (D) Common characteristics of Lekti2 and Lekti. The alignment of the Kazal domains of Lekti-2
and Lekti domains 2 and 15 were generated by using M-COFFEE, displayed by using GeneDoc and shown in the down panel. The middle panel shows
a schematic pattern of the typical Kazal domain including conserved tyrosine residue (Y) and disulfide bonds [14]. # represents the residue at the P1
site. The residue numbers spacing the cysteine residues are indicated on the top panel for the Kazal domain, LEKTI-2 and the LEKTI domains 2 and 15,
respectively.
doi:10.1371/journal.pone.0004372.g002
Figure 1. Identification of a new KLK5-inhibiting peptide in human stratum corneum. (A) RP-HPLC separation of extract stratum corneum
extracts from human plantar callus. Top, components eluting between 0% and 100% acetonitrile. Bottom, KLK5-inhibiting-activity of the fractions.
One out of three similar experiments is shown. Arrow indicates fractions with high activity to absorbance ratio at 20–21 min eluting time. (B) SDS
page analyses of fractions eluting between 18 and 22 minutes. Since the fractions were not collected by time but by peaks, distance of fractions is
not linear. A dominant peak of around 7 kDa is visible at 20–21 min eluting time. (C) ESI-MS analyses revealed a mass of 7058.18 kDa for the KLK5-
inhibiting fraction. (D) Edman degradation resulted in the indicated N-terminal sequence.
doi:10.1371/journal.pone.0004372.g001
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Our findings of LEKTI-2 and KLK5 expression are accordable to
those results but need further evaluation by electron microscopy.
However, LEKTI-2 expression was only detected in our studies at
palmar and plantar sites where a rigid SC is needed to protect the
hands and feet from mechanical damage. The fact that we did not
find LEKTI-2 immunoreactivity at other sites, though low mRNA
expression was detectable in skin samples, points to a minor role of
LEKTI-2 in non-plantar skin compared to LEKTI, which is
expressed throughout the entire skin. The circumstance that we
used plantar human callus as the natural source of KLK5 inhibitors
was therefore beneficial for the identification LEKTI-2. The
enhanced expression of LEKTI-2 in plantar clavus corroborates
the hypothesis that LEKTI-2-mediated KLK5 inhibition results in
suppressed desquamation. Clavi are often induced by abnormal
local mechanical pressure due to malformation of feet bones or tight
footgear. It will be interesting to study how LEKTI-2 expression is
induced by these mechanical forces. Mechanical stressrepresents an
important part of signaling in skin. Indeed, in vitro it induces
phosphorylation of keratin K6 and EGFR [19] and clustering of
beta1-integrins [20], and activates ERK1/2 [19] as well as Akt, one
of the kinases known to suppress apoptosis [21].
Most notably, LEKTI-2 exhibited only inhibiting activity
against tryptic KLK5 but not against the chymotryptic KLK7,
tryptic KLK14 or all other serine proteases tested including trypsin
and chymotrypsin. LEKTI-2 activity differs in this respect from
that of LEKTI, which contains multiple Kazal domains exhibiting
highly diverse inhibitory functions beyond others against trypsin,
Figure 3. Spink9 mRNA expression in human skin and keratinocytes. (A) Expression profile of Spink9 mRNA. Fragments were obtained after
RT-PCR amplification on human multiple tissue cDNAs with primers specific to the human GAPDH and Spink9. Lanes are labelled according to the
template tissue. The Spink9 fragments are of 175 bp in size. H2O (no cDNA) and RT-control (no RNA template) were used as negative controls. (B)
Spink9 mRNA expression in cultured primary keratinocytes. Quantitative realtime PCR was conducted on RT-PCR products of total RNA samples
collected from keratinocytes treated with 1.0 mM CaCl2 for the indicated time. Bar graphs represent the relative mRNA expression of Spink9 against
GAPDH. Data are obtained from three independent experiments with different sources of keratinocytes and are indicated as the mean+/2SD. *
indicates significant (p,0.05); ** indicates significant (p,0.01).
doi:10.1371/journal.pone.0004372.g003
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[15]. Therefore, the functions of both Kazal-type inhibitors are
suspected to be different. Overall trypsin-like and/or chymotryp-
sin-like activities resulting mainly from KLKs are considerably
elevated in the skin of Spink5-deficient mice [22] and in NS
patients [4,23]. The elevated activities cause increased degradation
of corneodesmosomal cadherins in NS patients [24]. It was shown
that KLKs are capable of cleaving corneodesmosomes, [7–10].
Furthermore, Kallikrein-mediated proteolysis regulates the anti-
microbial effects of cathelicidins in skin [25] and contributes to the
pathogenesis of rosacea [26]. Moreover, KLK5 and KLK14
haven been reported to activate the protease activated receptor
(PAR)-2 [27], a signaling receptor in epidermal inflammation [28]
and regulator of epidermal barrier function [29]. Altogether, these
accumulating data strongly suggest that in skin, KLKs are
desquamation-related serine proteases and that the balance
between serine proteases and inhibitors may be essential, not only
for steady desquamation but also for skin barrier function and
inflammation. Regulation of KLKs by endogenous proteinase
inhibitors like LEKTI and LEKTI-2 might therefore have
therapeutic potential in inflammatory skin diseases.
The Ki of LEKTI-2 against KLK5 observed herein can be
considered as preliminary since more in depth analysis of inhibition
was not possible in this studydue to limited accessto KLK5.Several
LEKTI domains have been reported to inhibit KLK5 in various
reports. In comparison, the determined Ki of LEKTI domains to
inhibit KLK5 was in the range of 3 nM (domain 8–11) to 120 nM
(domain 9–15) [9,30,31]. It will be very interesting to study the
inhibition of other KLKs by LEKTI-2 in future investigations.
KLKs are tryptic and chymotryptic enzymes though a detailed
comparison of their activities, substrates and specific inhibitors has
not been done systematically. As the most intensively studied KLK,
KLK3 (also known as prostate-specific antigen), is a chymotryptic
enzyme, similar in this respect to KLK7, which was not inhibited by
LEKTI-2. Since Spink9 mRNA was detected in other organs like
tonsils, testis, placenta and brain, but not in the prostate, it remains
speculative what function LEKTI-2 might have in other organs.
The only LEKTI-2 target enzyme identified so far is KLK5, which
was reported to be expressed at high levels (100–1000 ng/g tissue)
inbreast,testis,salivaryglandsand thyroidsbutintheskinathighest
reported levels (above 10,000 ng/g tissue) [32]. Detailed investiga-
tions of LEKTI-2 function in other organs are required to clarify its
role outside the skin.
In summary, we identified a new Kazal-type inhibitor LEKTI-2
and its gene Spink9 and showed its expression in human skin.
LEKTI-2 exhibited specific inhibition against KLK5, which might
beimportantindesquamationespeciallyatpalmarandplantarsites.
Materials and Methods
Material
All experiments were performed according to the Declaration of
Helsinki protocols and under protocols approved by the ethics
committees of the Medical Faculty of the Christians Albrechts
University Kiel, (Schwanenweg 20, D-24105 Kiel). Normal skin
specimens were taken from routine clinical work at the
Department of Dermatology, UKSH Kiel, and represent tumor-
free margins of benign melanocytic tumors surgically removed
from patients. Specimens of clavi were removed therapeutically
before written informed consents were received from the patients.
Restriction endonucleases were from New England Biolabs
(Frankfurt, Germany). KLK5, 7, and 14 were purchased from
R&D Systems, Minneapolis, MN. All other proteases, primers,
substrates and chemicals were purchased from Sigma–Aldrich
(Taufkirchen, Germany), if not otherwise indicated.
Protease Inhibition Assays
All protease assays were performed measuring chromogenic
substrate release by proteases. Following buffers were used: KLK5:
Figure 4. Western blot analyses of LEKTI-2 antibodies. Proteins
were separated in a 16.5% SDS-tricine polyacrylamide gel containing
8 M urea and blotted from both, the anode (left panel) and the cathode
(right panel) using protein transfer at pH 10.5. Recombinant and natural
LEKTI-2 used here have been HPLC-purified, stored below 270uC and
used immediately prior to experiments unless otherwise stated. Lanes 1
and 7: Precisions Plus Protein Dual Color standards Biorad (it includes
peroxidase-active markers), each 3 ml; lane 2: stratum corneum extract,
20 ml; lane 3: rLEKTI-2 (200 ng); lane 4: stratum corneum extract, 40 ml;
lane 5: natural LEKTI-2 from stratum corneum extract (off RP-8-HPLC,
see Fig. 1A), 30 ml; lane 6: rLEKTI-2 (200 ng). WB analyses performed
with LEKTI-2 antibodies, pretreated for 1 h with 20 mg r LEKTI-2, did not
show any LEKTI-2 immunostaining, which further confirms specificity of
the LEKTI-2 antibodies. Note that cathodal transfer seems to be more
efficient than anodal protein transfer. A representative out of three
independent experiments is shown.
doi:10.1371/journal.pone.0004372.g004
Figure 5. LEKTI-2 is expressed at palmar and plantar sites.
Immunohistochemical staining (Vector red) of LEKTI-2 of paraffin-
embedded human skin samples using polyclonal antibodies. Only
palmar and plantar localizations (A, n=8) exhibited obvious LEKTI-2
immunoreactivity at the stratum granulosum and stratum corneum.
Other localizations (e.g. trunk, B, n=16) did not reveal LEKTI-2
immunoreactivity. Bars indicate 50 mm.
doi:10.1371/journal.pone.0004372.g005
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HCl, 0.15 M NaCl, pH 8.0, at 21uC. All other proteases (Table 1)
were measured in the buffer recommended by the manufacturer.
Specific concentrations of protease, substrate and inhibitor are
indicated in Table 1. The changes of absorbance at 405 nm were
followed up to 16 h in comparison with enzyme-free controls.
Figure 6. Inhibition of KLK5 by rLEKTI-2. (A) Enzyme kinetic of KLK5 (5 nM) and LEKTI-2 (0 to 2000 nM) in comparison to no inhibition of KLK14
(B), KLK7 (C), trypsin (D) and chymotrypsin (E). The substrate for KLK5 was MeO-Suc-Arg-Pro-Tyr-pNA (1 mM). Points represent mean of triplicate
experiments and the solid line represents the fitted curve according to equation of Baici model [33].
doi:10.1371/journal.pone.0004372.g006
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enzyme with inhibitor or HPLC fraction for 15 min at 21uC. Km
was determined for KLK5 using various concentrations of
substrate. Ki was calculated using Baici Model [33] assuming full
competitivity of binding.
Isolation of KLK5 inhibitor from human stratum corneum
Total proteins were extracted from heel stratum corneum, a
clinical circumstance when desquamation might be inhibited by
KLK-inhibitors, with an acidic buffer. Briefly, pooled heel stratum
corneum (80–120 grams) was extracted with acidic ethanolic
citrate buffer as described [34]. After diafiltration (Amicon filters,
cut off: 3 kDa) against 10 mM Tris/citrate buffer, pH 8.0, extracts
were applied to a heparin-sepharose cartridge (1065 mm,
Pharmacia, Freiburg, FRG), previously equilibrated with the
diafiltration buffer. After washing, bound proteins were eluted
with 2 ml 2 M NaCl in 0.1 M Tris/citrate buffer and the heparin-
bound material was further diafiltrated against 0.1% (v/v)
trifluoroacetic acid (TFA) in HPLC grade water. Heparin-bound
material was purified by preparative wide-pore reversed phase
high-performance liquid chromatography (RP-HPLC) using a
column (30067 mm, C8 Nucleosil, 250612.6 mm, Macherey and
Nagel, Du ¨ren, Germany) that was previously equilibrated with
0.1% (v/v) TFA in HPLC grade water containing 20% (v/v)
acetonitrile. Proteins were eluted with a gradient of increasing
concentrations of acetonitrile containing 0.1% (v/v) TFA (flow
rate: 2 ml/min). Aliquots (10–30 ml) of each fraction were
lyophilized, dissolved in 5 ml 0.1% (v/v) aqueous acetic acid and
tested for protease-inhibiting activity.
Fractions containing KLK5-inhibiting activity, eluting at low
(25%) acetonitrile were further purified by micro-C2/C18-RP-
HPLC and tested for KLK5-inhibiting activity. Protease-inhibiting
activity-containing HPLC fractions were further analyzed by
Electrospray-ionization mass spectrometry (ESI-MS) in the
positive ionization mode with a quadrupole orthogonal acceler-
ating time-of-flight mass spectrometer (QTOF-II hybrid mass
spectrometer; Micromass, Manchester, United Kingdom). Con-
centrations of proteins present in HPLC fractions were estimated
via UV-absorbance integration at 215 nm using ubiquitine for
calibration. The N-terminal amino acid sequence of the principal
protein was determined using a pulsed-liquid-phase 776 automat-
ed protein sequencer (Perkin Elmer Applied Biosystems, Massa-
chusetts, USA).
In silico analyses
Homology search was done using the BLAT algorithm [35] as
provided by the UCSC Genome Browser (http://genome.ucsc.
edu/cgi-bin/hgBlat) and the BLAST algorithm [36] as provided
by the Ensembl server (http://www.ensembl.org/Multi/
blastview). Subsequent sequence manipulations utilized the online
BLAST 2 Sequences [37] (http://www.ncbi.nlm.nih.gov/ blast/
bl2seq/bl2.html). Splice site analysis was performed using the
FSPLICE program implemented at the SoftBerry server (http://
www.softberry.com/berry.phtml). Protein domains were discov-
ered on the SMART server [38]. Multiple sequence alignments
were performed using the M-coffee program [39] and edited with
GeneDoc (http://www.psc.edu/biomed/genedoc).
Rapid amplification of cDNA ends (RACE)
Total RNA was obtained from cultured human foreskin-derived
keratinocytes using TRIzol reagent (Invitrogen, Hamburg, Ger-
many).AftertreatmentwithRNase-freeDNaseI(Roche Diagnostics,
Mannheim, Germany) to exclude contamination with genomic
DNA, 3 mg of DNA-free total RNA was used for the first-strand
cDNA synthesis for RACE using SMART RACE cDNA Amplifi-
cation Kit (BD Bioscience Clontech, Heidelberg, Germany)
according to the manufacturer’s protocol. To obtain the 59-end of
Spink9 cDNA, a 59-RACE was performed with a gene-specific
antisense primer (59-TGC CAT CAG ATC CAC AAA TTG GAT
CAT AC-39) and a universal primer mix (106 UPM) essentially
according to the manufacturer’s protocol. 59-RACE PCR reaction
cycleswere performed with an annealing temperature of68uCand35
cycles.Toobtainthe39-end of Spink9cDNA,thefirstroundPCRwas
performed with a gene-specific sense primer (59-GCC AAA CAG
A C GA A AC A GA T GG T TG A CT - 3 9)a n d1 0 6 UPM.
Subsequently, 0.5 ml of PCR products was used as a template for a
nested PCR with a nested gene-specific sense primer (59-ACC ACC
AGG ACA ACA GAG ATT TTG TCA TC-39)a n dan e s t e d
universal primer (NUP) under the following conditions: 1 min at
95uC, 30 cycles of 20 s at 95uCa n d3m i na t7 0 uC, and a final
extension of 10 minat 70uC.Theamplifiedfragmentwasgelpurified
and subcloned into the pGEM-T vector (Promega, Mannhein,
Germany) followed by fully sequencing in both directions.
mRNA expression analyses
A total of 2 mg of total RNA from human skin samples or
cultured foreskin-derived keratinocytes was reverse transcribed
Table 1. Protease Inhibition by rLEKTI-2.
Proteinase (final concentration) LEKTI-2 (nM) Inhibition (%) Substrate (0.33 mM)
Bovine Trypsin (2 nM) 400 0 N-(p-Tosyl)-Arg-Gly-Val 5-nitroanilide
Cathepsin G (1 nM) 666 0 N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide
Chymase (2 nM) 666 0 N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide
Human Chymotrypsin (2 nM) 400 0 3-Carbomethoxypropionyl-Arg-Pro-Tyr p-nitroaniline
KLK14 (2 nM) 400 0 N(p-Tosyl)-Arg-Gly-Val 5-nitroanilide
KLK5 (5.3 nM) 400 91.8 N(p-Tosyl)-Arg-Gly-Val 5-nitroanilide
KLK7 (15.8 nM) 400 0 3-Carbomethoxypropionyl—Arg-Pro-Tyr p-nitroaniline
Human leukocyte elastase (2 nM) 400 0 N-Methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide
Human Plasmin (2 nM) 400 0 N-(p-Tosyl)-Gly-Pro-Lys 4-nitroanilide
Human Thrombin (1 nM) 400 0 N-(p-Tosyl)-Gly-Pro-Arg p-nitroanilide
Matriptase (0.5 nM) 400 0 H-D-Ile-Pro-Arg p-nitroaniline
doi:10.1371/journal.pone.0004372.t001
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2 reverse
transcriptase (Invitrogen, Hamburg, Germany). For following
PCR analysis, one pair of gene-specific PCR primers (forward
primer: 59-GAC ACC AGG TCA CTT CTT TTC CCT ACA
TC-39; reverse primer: 59-TCT ACA TAT GGT GAT GAG
TAG GCA ATG TG-39) were designed to amplify a 422-bp
product and to span all three exon-intron boundaries. PCR
amplifications were carried out for 35 cycles of 20 s at 95uC
followed by 30 s at 72uC using Advantage 2 Polymerase Mix (BD
Bioscience Clontech, Heidelberg, Germany). PCR products were
analyzed by 2.0% agarose gel electrophoresis. Because of low
expression of Spink9 mRNA in most tissues and cells, all PCR
products above were then diluted 20-fold in water and used for
nested PCR and real-time PCR. For nested PCR, another pair of
intron-spanning primers (forward primer: 59-ACT TGC AAC
CAT GTT CAG TAT AGA-39; reverse primer: 59-AAC TTT
AGA ACA GAA GAA GCA ATC A-39) was designed to amplify a
175-bp product. PCR products were then analyzed by 2.0%
agarose gel electrophoresis.
As an internal controlof cDNA templates, the housekeeping gene
GAPDH (glyceraldehyde phosphodehydrogenase) was assessed with
each cDNA in a separate PCR reaction. For quantitative real-time
RT-PCR, assay was carried out with the first primer pair as above
and the SYBRH Premix Ex Taq
TM Kit (Takara Bio, Heidelberg,
Germany) in a fluorescence thermocycler following the instructions
of the manufacturer (LightCycler, Roche Molecular Biochemicals,
Hamburg, Germany). During the evaluation phase of the assay,
amplicons were analyzed by 2.0% agarose gel electrophoresis and,
where necessary purified and sequenced to confirm their identity.
For calculation of the relative transcripts amplification, the
housekeeping gene GAPDH was performed with each cDNA in a
separate PCR reaction. The data from triplicate samples were
analyzed with software (GraphPad Prism 4) and expressed as
mean6SD of mRNA in question relative to that of GAPDH. The
statistical analyses were performed with One-way ANOVA method
and p,0.05 was considered significant while p,0.01 was
considered very significant.
Recombinant protein production
The recombinant expression of Spink9 cDNA in E. coli was
performed by molecular subcloning of Spink9 cDNA into the
prokaryotic expression vectors pET-32a (Novagen, North Ryde,
Australia). The purified form of LEKTI2 (amino acid 26 to 86)
was generated as PCR fragments (Primer sequences are available
upon request) by using Pfu DNA polymerase (Promega, Man-
nhein, Germany). PCR products were double-digested with BglII
and NotI prior to be cloned into the similarly double-digested pET-
32a vectors. Clones were sequenced to check for any mutation that
might have been misincorporated during the amplification. The
expression construct was transformed into Escherichia coli (E. coli)
BL21trxB(DE3)pLysS cells (Novagen) and selected on Luria-Bertani
(LB) agar plates containing carbenicillin (100 mg/ml), chloram-
phenicol (34 mg/ml) and kanamycin (15 mg/ml). Protein expres-
sion was induced with 1 mM IPTG (isopropyl thio-b-D-galacto-
side) for a 3 h. After incubation, cells were harvested by
centrifugation and resuspended in 16LEW buffer (50 mM
NaH2PO4, 300 mM NaCl, pH 8.0). Resuspended cells were
subjected to one cycle of freeze-thawing and sonicated on ice until
complete lyses. After centrifugation at 15,5006g for 30 min, the
clarified supernatant was applied to ProtinoHNi prepared columns
(Macherey-Nagel, Dueren, Germany) and the polyhistidine-tagged
protein was eluted with 16elution buffer (50 mM NaH2PO4,
300 mM NaCl, 250 mM imidazole, pH 8.0). The further
Figure 8. LEKTI-2 is highly expressed at sites of hyperkeratosis.
Immunohistochemical staining (Vector red) of LEKTI-2 of a paraffin-
embedded section of a clavus. Notice the enormously enlarged stratum
corneum (hyperkeratosis) in the upper two third of the picture with a
sweat gland sectioned at the upper first third. Clefts between the
stratum corneum and the stratum granulosum are artefacts derived
from histology processing. The upper part of the living epidermis, the
stratum granulosum, exhibits a massive increase in LEKTI-2 immuno-
reactivity (red). A representative result out of three different samples of
clavi is shown.
doi:10.1371/journal.pone.0004372.g008
Figure 7. LETKI-2 and KLK5 are expressed at the stratum granulosum of palmar skin. Immunofluorescence localization of LEKTI-2 (red)
and KLK5 (green) in human skin. Nuclei staining was done using Hoechst 33258 reagent. (B–E) shows the magnification of the white-square area of
(A). LEKTI-2 staining showed granular structures inside the keratinocytes at the stratum granulosum (C) with a faint intercellular staining pattern and
remaining immunoreactivity inside the stratum corneum. KLK5 staining (D) exhibited only intercellular staining at the stratum granulosum.
Comparative localization of LEKTI-2 and KLK5 is shown in the merged image (D). (E) shows the control omitting the first antibody.
doi:10.1371/journal.pone.0004372.g007
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high-performance liquid chromatography (RP-HPLC) using
preparative wide-pore C8 RP-HPLC with a column (SP250/10
Nucleosil 300-7 C8; Macherey-Nagel) that was previously
equilibrated with 0.1% (v/v) TFA in HPLC-grade water
containing 10% acetonitrile. Proteins were eluted with a gradient
of increasing concentrations of acetonitrile containing 0.1% (v/v)
TFA (flow rate, 3 ml/min). Fractions containing UV (215 nm)-
absorbing material were collected, lyophilized and analyzed by
ESI-QTOF-mass spectrometry (Micromass, Manchester, U.K.).
The His-tagged fusion protein purified from HPLC-RP8 was
cleaved from its His-tag with SUMO protease according to the
manufacturer’s suggestion (Lifesensors Inc., Pennsylvania, USA).
The digestion mixture contained 1 unit of SUMO protease per
100 mg of the fusion protein in a volume of 500 mlo f1 6PBS
buffer and was incubated for 2 h at 30uC. The dialyzed sample
was adjusted to a pH value of 3.0 to 4.0 and then purified by
centrifugation. The supernatant was collected and injected onto a
Jupiter-5m-C4-300A HPLC column (Phenomenex, Aschaffenburg,
Germany) equilibrated with 0.1% TFA in water. Peptides were
eluted with a gradient of increasing concentrations of acetonitrile
containing 0.1% (v/v) TFA (flow rate, 0.5 ml/min). Fractions of
each peak were collected, lyophilized and analyzed by ESI-
QTOF-mass spectrometry.
Production of antibodies
Polyclonal antiserum was generated in a goat against a full
length peptide with the amino-acid sequence of human LEKTI-2
(amino acid 26 to 86). A total of 1.0 mg of protein mixture
including 500 mg of fusion protein (pET-32a-LEKTI-2-3) and
500 mg of HPLC-purified recombinant peptide was conjugated by
the glutaraldehyde method to maleimide-activated keyhole limpet
hemocyanin (KLH) (protein-KLH 1 : 1, w/w) and subsequently
mixed with 500 mg of pET-32a-lekri-2-3 for use as immunogens.
Immunization of a goat was carried out four times on days 0, 14,
28 and 35. Goats were bled 2 weeks after the last booster. The
serum was separated from the clot and stored at 270uC until
required. Antisera were affinity-purified by absorption against
rLEKTI-2-3 that was covalently bound to HiTrap NHS-activated
HP 1 ml columns (Amersham Biosciences, Freiburg, Germany).
Specificity was tested by immuno-dot analyses and Western blot
analyses using purified rLEKTI-2, purified natural LEKTI-2 and
stratum corneum extracts.
Western blot analyses
For Western-blot analysis healthy persons’ stratum corneum
extract, HPLC-fractions containing natural LEKTI-2 or recom-
binant LEKTI-2, were loaded onto a 16.5% SDS-tricine
polyacrylamide gel containing 8 M urea. Proteins were transferred
to a Protran-nitrocellulose membrane (Schleicher & Schuell
BioScience, Dassel, Germany), blocked for 1 h in blocking buffer
(5% (w/v) nonfat powdered milk in PBS+0.05% Tween), then
incubated for 18 h at 4uC in 3% (w/v) nonfat powdered milk in
PBS+0.05% Tween containing 1:1,250 affinity-purified polyclonal
LEKTI-2 antibody. The membrane was washed with PBS+0.05%
Tween six times for 5 min each, then incubated for 1 h in 3% (w/
v) nonfat powdered milk in PBS+0.05% Tween containing
1:20,000 dilution of goat anti-mouse IgG HRP conjugate
(Dianova, Hamburg, Germany). After six times washing steps as
before the membrane was incubated for 5 min with chemilumi-
nescent peroxidase substrate (Sigma, Taufkirchen, Germany) and
visualized using a Diana III cooled CCD-camera imaging system
(Raytest, Straubenhardt, Germany). Densitometric quantifications
were performed using AIDA evaluation software (Raytest).
Cell culture
Foreskin-derived primary keratinocytes were prepared from
neonatal foreskin after surgery following established methods [40]
and were cultured in Epilife medium in 75-cm
2 flasks (BD
Biosciences, Heidelberg, Germany) in a humidified atmosphere
with 5% CO2. For stimulation and RNA isolation, cells were
grown in 12-well tissue culture plates (BD Biosciences) and were
used after the second passage at a confluence of 70–80%.
Stimulation was performed for the indicated time with 1.0 mM
of freshly prepared CaCl2 for the indicated time.
Immunohistochemistry
Fixation of the tissue samples was performed in 4% parafor-
maldehyde. Paraffin sections (5 mm) of the tissue samples were
deparaffinised and rehydrated before heat-induced antigen
retrieval was performed in 0.01 M citrate buffer (pH 6.0). The
slides were blocked with normal rabbit serum (1:75, Dako
Cytomation, Glostrup, Denmark) before staining. Immunohisto-
chemical staining was performed at room temperature for one
hour using with affinity-purified polyclonal goat anti-lekti-2
antibody (1:200 dilutions. A biotinylated secondary rabbit anti-
goat IgG (1:100, Dako Cytomation) antibody was used, followed
by incubation with Vector Universal ABC Alkaline Phophatase
Substrate Kit (Vector, Burlingame, CA, USA) developed with
Vector NovaRED Substrate (Vector) and counterstained with
hematoxylin. Specificity test of the anti- lekti-2 antibody was
performed by using recombinant lekti-2 peptides to block the
primary antibody. Negative controls were established by using
preimmune goat sera to stain sections.
Immunofluorescence
To show the potential spatial relationships between LEKTI-2
and KLK5, the paraffin-embedded skin sections (5 mm) were
blocked with 10% normal goat and rabbit sera (Vector) in TBS
containing 0.1% BSA and 0.2% glycine after standard rehydra-
tion. Sections were incubated with a mixture of anti-LEKTI2
antibody (1:100 dilution) and a rabbit anti-KLK5 antibody (1:200
dilution; Jackson R&D systems, Minneapolis, MN). After washing,
they were incubated with a mixture of secondary antibodies (Cy3-
coupled pig-antigoat IgG and Cy2-coupled chicken-antirabbit
IgG, diluted 1:400 each; Dianova, Hamburg, Germany) for 1 h at
room temperature. Sections were counterstained with the DNA-
selective bisbenzimide dye (blue; Hoechst 33258). To exclude
artificial autofluorescence secondary to the preparation of the
sections, control sections were stained without primary antibodies
and no unspecific labeling was observed following incubation with
secondary antibodies (data not shown). Slides were analyzed using
a confocal laser scanning microscopy (Zeiss, LSM 510 UV, Jena,
Germany).
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